Turmeric in a shot? early test for Tough-to-Treat blood cancer
NCT ID NCT07456605
Summary
This is a very early study to find the safest dose of a new IV drug made from curcumin, the active part of turmeric. It will involve 20 adults with advanced multiple myeloma that has returned or stopped responding to all standard treatments. The main goal is to see what side effects occur and determine the highest dose patients can tolerate without severe problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network-Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.